923947-18-6

Basic information

• Product Name: Thiazole, 4-methyl-2-(4-methyl-2-nitrophenyl)-
• CAS NO: 923947-18-6
• Molecular Formula: C11H10N2O2S
• Molecular Weight: 234.279
• Mol File: 923947-18-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Thiazole, 4-methyl-2-(4-methyl-2-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazole, 4-methyl-2-(4-methyl-2-nitrophenyl)-(923947-18-6)
• EPA Substance Registry System: Thiazole, 4-methyl-2-(4-methyl-2-nitrophenyl)-(923947-18-6)

Safety Data

• Hazardous Substances Data: 923947-18-6(Hazardous Substances Data)

Upstream product

• 923945-96-4 4-methyl-2-nitro-thiobenzamide 
• 126-38-5 1-bromo-2,2-dimethoxypropane 

Relevant articles and documents

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.